| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 32 | 2019 | 166 | 6.470 |
Why?
|
| Uveal Neoplasms | 22 | 2019 | 25 | 5.350 |
Why?
|
| MicroRNAs | 6 | 2016 | 181 | 1.830 |
Why?
|
| Melanoma, Experimental | 4 | 2012 | 10 | 1.330 |
Why?
|
| Immunotherapy | 7 | 2019 | 91 | 1.150 |
Why?
|
| Cancer Vaccines | 8 | 2010 | 25 | 1.110 |
Why?
|
| Adenocarcinoma | 5 | 2013 | 298 | 0.980 |
Why?
|
| Killer Cells, Natural | 3 | 2016 | 21 | 0.980 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 2013 | 25 | 0.950 |
Why?
|
| Chromosomes, Human, Pair 3 | 5 | 2016 | 28 | 0.870 |
Why?
|
| Neovascularization, Pathologic | 4 | 2013 | 75 | 0.860 |
Why?
|
| Dendritic Cells | 8 | 2013 | 62 | 0.790 |
Why?
|
| Recombinant Proteins | 11 | 2013 | 263 | 0.780 |
Why?
|
| Azacitidine | 3 | 2012 | 27 | 0.720 |
Why?
|
| Antineoplastic Agents | 7 | 2019 | 595 | 0.690 |
Why?
|
| Dacarbazine | 5 | 2019 | 31 | 0.690 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2012 | 48 | 0.690 |
Why?
|
| Interferon-alpha | 4 | 2019 | 68 | 0.680 |
Why?
|
| Humans | 58 | 2020 | 32284 | 0.670 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2011 | 8 | 0.660 |
Why?
|
| Cell Proliferation | 8 | 2011 | 599 | 0.650 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2016 | 257 | 0.600 |
Why?
|
| Monosomy | 2 | 2016 | 5 | 0.580 |
Why?
|
| Adjuvants, Immunologic | 3 | 2010 | 60 | 0.570 |
Why?
|
| Adenoviridae | 4 | 2013 | 66 | 0.570 |
Why?
|
| Antigens, Neoplasm | 3 | 2015 | 38 | 0.560 |
Why?
|
| Cytokines | 10 | 2013 | 236 | 0.560 |
Why?
|
| Genetic Vectors | 7 | 2011 | 109 | 0.550 |
Why?
|
| Colorectal Neoplasms | 4 | 2013 | 220 | 0.540 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2013 | 34 | 0.540 |
Why?
|
| Immunity, Cellular | 3 | 2015 | 21 | 0.530 |
Why?
|
| Mice | 15 | 2019 | 2544 | 0.520 |
Why?
|
| Chromosome Deletion | 3 | 2015 | 11 | 0.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2014 | 442 | 0.520 |
Why?
|
| Female | 32 | 2020 | 19954 | 0.500 |
Why?
|
| Male | 32 | 2020 | 19434 | 0.500 |
Why?
|
| Injections, Intralesional | 4 | 2018 | 16 | 0.480 |
Why?
|
| Angiogenic Proteins | 2 | 2013 | 10 | 0.480 |
Why?
|
| Prostatic Neoplasms | 3 | 2012 | 489 | 0.470 |
Why?
|
| Aged | 24 | 2019 | 10257 | 0.470 |
Why?
|
| Middle Aged | 26 | 2020 | 11843 | 0.470 |
Why?
|
| Immunity, Humoral | 1 | 2015 | 14 | 0.460 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 93 | 0.460 |
Why?
|
| Skin Neoplasms | 2 | 2011 | 220 | 0.460 |
Why?
|
| Interleukin-12 | 3 | 2005 | 29 | 0.450 |
Why?
|
| Neoplasms | 5 | 2018 | 763 | 0.450 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2015 | 62 | 0.440 |
Why?
|
| Epigenesis, Genetic | 2 | 2016 | 107 | 0.440 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2012 | 17 | 0.440 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2012 | 7 | 0.420 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2014 | 113 | 0.410 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2013 | 101 | 0.390 |
Why?
|
| beta 2-Microglobulin | 1 | 2013 | 5 | 0.380 |
Why?
|
| Animals | 16 | 2019 | 8165 | 0.380 |
Why?
|
| Adult | 21 | 2020 | 9263 | 0.380 |
Why?
|
| Mice, Inbred C57BL | 7 | 2012 | 776 | 0.380 |
Why?
|
| Interleukin-2 | 2 | 2012 | 38 | 0.370 |
Why?
|
| Myeloid Cells | 1 | 2012 | 39 | 0.360 |
Why?
|
| Aged, 80 and over | 12 | 2019 | 3896 | 0.360 |
Why?
|
| Cell Movement | 1 | 2012 | 165 | 0.360 |
Why?
|
| Antibodies, Monoclonal | 4 | 2010 | 246 | 0.360 |
Why?
|
| Liver Neoplasms | 2 | 2011 | 164 | 0.340 |
Why?
|
| Endothelial Cells | 1 | 2012 | 190 | 0.340 |
Why?
|
| Prognosis | 8 | 2020 | 1529 | 0.340 |
Why?
|
| Plasmids | 4 | 2005 | 53 | 0.330 |
Why?
|
| Cell Line, Tumor | 8 | 2019 | 726 | 0.330 |
Why?
|
| Interferon-beta | 1 | 2011 | 19 | 0.330 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2010 | 10 | 0.330 |
Why?
|
| Neoplasm Metastasis | 8 | 2019 | 222 | 0.330 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2015 | 43 | 0.320 |
Why?
|
| Treatment Outcome | 10 | 2018 | 3410 | 0.310 |
Why?
|
| RNA, Messenger | 7 | 2014 | 499 | 0.310 |
Why?
|
| Antirheumatic Agents | 1 | 2010 | 28 | 0.310 |
Why?
|
| Taxoids | 2 | 2010 | 50 | 0.300 |
Why?
|
| Dependovirus | 2 | 2010 | 18 | 0.290 |
Why?
|
| Membrane Proteins | 1 | 2010 | 243 | 0.290 |
Why?
|
| Piperazines | 1 | 2008 | 60 | 0.280 |
Why?
|
| Mesothelioma | 2 | 2006 | 33 | 0.270 |
Why?
|
| Pyrimidines | 1 | 2008 | 77 | 0.270 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2005 | 8 | 0.270 |
Why?
|
| Peptide Fragments | 1 | 2010 | 417 | 0.260 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2006 | 4 | 0.250 |
Why?
|
| Gangliosides | 1 | 2006 | 7 | 0.250 |
Why?
|
| Antibodies, Neoplasm | 3 | 2004 | 15 | 0.250 |
Why?
|
| Brain Neoplasms | 3 | 2020 | 636 | 0.250 |
Why?
|
| Radiosurgery | 2 | 2020 | 355 | 0.240 |
Why?
|
| Vaccines, DNA | 2 | 2005 | 6 | 0.240 |
Why?
|
| Neoplasm Proteins | 2 | 2015 | 146 | 0.240 |
Why?
|
| Diphtheria-Tetanus Vaccine | 1 | 2005 | 1 | 0.230 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2005 | 9 | 0.230 |
Why?
|
| Vaccines, Synthetic | 2 | 2005 | 15 | 0.230 |
Why?
|
| T-Lymphocytes | 1 | 2006 | 138 | 0.230 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2005 | 34 | 0.230 |
Why?
|
| Apoptosis | 4 | 2011 | 367 | 0.230 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2011 | 113 | 0.220 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2015 | 151 | 0.220 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 246 | 0.220 |
Why?
|
| Fowlpox | 1 | 2005 | 1 | 0.220 |
Why?
|
| Avipoxvirus | 1 | 2005 | 1 | 0.220 |
Why?
|
| Cell Differentiation | 3 | 2012 | 452 | 0.220 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2019 | 44 | 0.220 |
Why?
|
| Promoter Regions, Genetic | 3 | 2011 | 203 | 0.210 |
Why?
|
| Neoplasms, Experimental | 1 | 2004 | 33 | 0.210 |
Why?
|
| Kidney Neoplasms | 3 | 2011 | 200 | 0.210 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2019 | 54 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 4 | 2014 | 165 | 0.200 |
Why?
|
| Antigens, CD34 | 1 | 2003 | 48 | 0.190 |
Why?
|
| Immunoenzyme Techniques | 3 | 2014 | 47 | 0.190 |
Why?
|
| Colonic Neoplasms | 1 | 2003 | 70 | 0.190 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2014 | 23 | 0.180 |
Why?
|
| Chorionic Gonadotropin | 1 | 2002 | 6 | 0.180 |
Why?
|
| Mice, Nude | 3 | 2011 | 285 | 0.180 |
Why?
|
| Diphtheria Toxin | 1 | 2002 | 30 | 0.180 |
Why?
|
| Combined Modality Therapy | 3 | 2012 | 550 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 1 | 2003 | 131 | 0.180 |
Why?
|
| Drug Therapy, Combination | 3 | 2011 | 293 | 0.170 |
Why?
|
| Neoplasm Transplantation | 3 | 2019 | 73 | 0.170 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2005 | 122 | 0.170 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 325 | 0.170 |
Why?
|
| Prostate-Specific Antigen | 3 | 2013 | 59 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2019 | 185 | 0.170 |
Why?
|
| Survival Rate | 5 | 2019 | 892 | 0.170 |
Why?
|
| Cells, Cultured | 3 | 2010 | 821 | 0.170 |
Why?
|
| Young Adult | 4 | 2019 | 2652 | 0.160 |
Why?
|
| Aminoquinolines | 2 | 2011 | 18 | 0.160 |
Why?
|
| Radiopharmaceuticals | 2 | 2019 | 93 | 0.160 |
Why?
|
| Flow Cytometry | 2 | 2011 | 184 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 4 | 2019 | 199 | 0.160 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2019 | 56 | 0.150 |
Why?
|
| Plasma Cells | 1 | 2019 | 12 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 1052 | 0.150 |
Why?
|
| Syndecan-1 | 1 | 2019 | 20 | 0.150 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2019 | 6 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2016 | 160 | 0.140 |
Why?
|
| Organoids | 1 | 2019 | 101 | 0.140 |
Why?
|
| Vaccination | 3 | 2005 | 156 | 0.140 |
Why?
|
| Luminescent Measurements | 1 | 2018 | 16 | 0.130 |
Why?
|
| Oncolytic Virotherapy | 1 | 2018 | 16 | 0.130 |
Why?
|
| Transduction, Genetic | 4 | 2005 | 37 | 0.130 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 70 | 0.130 |
Why?
|
| Models, Biological | 1 | 2019 | 403 | 0.130 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 322 | 0.130 |
Why?
|
| Autoantibodies | 2 | 2015 | 50 | 0.130 |
Why?
|
| Melanocytes | 1 | 2016 | 8 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2019 | 2320 | 0.120 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2016 | 16 | 0.120 |
Why?
|
| Interferon-gamma | 3 | 2005 | 60 | 0.120 |
Why?
|
| Biomarkers, Pharmacological | 2 | 2014 | 5 | 0.120 |
Why?
|
| Transfection | 1 | 2016 | 198 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2011 | 372 | 0.120 |
Why?
|
| Lymphocyte Count | 2 | 2013 | 25 | 0.110 |
Why?
|
| Isotope Labeling | 1 | 2015 | 14 | 0.110 |
Why?
|
| False Negative Reactions | 1 | 2015 | 22 | 0.110 |
Why?
|
| Immunologic Factors | 2 | 2013 | 53 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 880 | 0.110 |
Why?
|
| Blotting, Western | 3 | 2015 | 297 | 0.110 |
Why?
|
| Thalidomide | 2 | 2013 | 32 | 0.110 |
Why?
|
| DNA, Recombinant | 2 | 2005 | 6 | 0.110 |
Why?
|
| Visual Acuity | 1 | 2015 | 76 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2014 | 858 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2012 | 709 | 0.110 |
Why?
|
| Proteomics | 1 | 2015 | 96 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 24 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 2 | 2005 | 38 | 0.110 |
Why?
|
| Clinical Trials as Topic | 3 | 2015 | 312 | 0.110 |
Why?
|
| Immunomagnetic Separation | 1 | 2014 | 4 | 0.110 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2014 | 22 | 0.100 |
Why?
|
| Anxiety | 1 | 2016 | 195 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2016 | 229 | 0.100 |
Why?
|
| Lymphocyte Activation | 2 | 2005 | 94 | 0.100 |
Why?
|
| Gene Targeting | 2 | 2003 | 15 | 0.100 |
Why?
|
| Decision Making | 1 | 2016 | 190 | 0.100 |
Why?
|
| Adenoviruses, Human | 2 | 2003 | 28 | 0.100 |
Why?
|
| Indoles | 2 | 2014 | 64 | 0.100 |
Why?
|
| Pyrroles | 2 | 2014 | 58 | 0.100 |
Why?
|
| Eye Enucleation | 1 | 2013 | 5 | 0.100 |
Why?
|
| Tissue Distribution | 1 | 2013 | 64 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2019 | 554 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 22 | 0.100 |
Why?
|
| Brachytherapy | 1 | 2013 | 29 | 0.090 |
Why?
|
| Drug Dosage Calculations | 1 | 2012 | 6 | 0.090 |
Why?
|
| Depression | 1 | 2016 | 427 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 84 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2012 | 77 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2011 | 114 | 0.090 |
Why?
|
| Genes, p53 | 1 | 2012 | 22 | 0.090 |
Why?
|
| Immunosuppression | 1 | 2012 | 118 | 0.090 |
Why?
|
| Antimony Sodium Gluconate | 1 | 2011 | 1 | 0.090 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2012 | 25 | 0.090 |
Why?
|
| Endothelin-1 | 1 | 2011 | 21 | 0.090 |
Why?
|
| Tetrahydrouridine | 1 | 2011 | 1 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2011 | 9 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2011 | 3 | 0.090 |
Why?
|
| SOX9 Transcription Factor | 1 | 2011 | 12 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2011 | 8 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2011 | 23 | 0.090 |
Why?
|
| Injections, Intraperitoneal | 1 | 2011 | 45 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2012 | 89 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 135 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 650 | 0.080 |
Why?
|
| BCG Vaccine | 1 | 2011 | 8 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2011 | 80 | 0.080 |
Why?
|
| Base Sequence | 1 | 2011 | 256 | 0.080 |
Why?
|
| Cyclooxygenase 2 | 1 | 2011 | 51 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2011 | 66 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2011 | 190 | 0.080 |
Why?
|
| Logistic Models | 1 | 2013 | 743 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2011 | 77 | 0.080 |
Why?
|
| Interleukin-10 | 1 | 2010 | 30 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2011 | 85 | 0.080 |
Why?
|
| Immunomodulation | 1 | 2010 | 27 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2011 | 144 | 0.080 |
Why?
|
| Safety | 2 | 2018 | 65 | 0.080 |
Why?
|
| Extracellular Fluid | 1 | 2010 | 16 | 0.080 |
Why?
|
| Disease Progression | 1 | 2012 | 590 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 555 | 0.070 |
Why?
|
| Th1 Cells | 2 | 2011 | 23 | 0.070 |
Why?
|
| DNA | 1 | 2010 | 222 | 0.070 |
Why?
|
| Phenotype | 1 | 2011 | 619 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2014 | 716 | 0.070 |
Why?
|
| Macrophages | 1 | 2010 | 164 | 0.070 |
Why?
|
| Research Design | 1 | 2011 | 316 | 0.070 |
Why?
|
| Benzamides | 1 | 2008 | 60 | 0.070 |
Why?
|
| Antibody Formation | 2 | 2005 | 47 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 1 | 2008 | 62 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 74 | 0.070 |
Why?
|
| CD40 Ligand | 2 | 2004 | 12 | 0.060 |
Why?
|
| Receptors, Virus | 2 | 2004 | 12 | 0.060 |
Why?
|
| Capsid Proteins | 2 | 2003 | 9 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 105 | 0.060 |
Why?
|
| Gene Expression | 2 | 2005 | 345 | 0.060 |
Why?
|
| Receptors, Fc | 1 | 2006 | 6 | 0.060 |
Why?
|
| Diphosphonates | 1 | 2006 | 9 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2019 | 309 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 2238 | 0.060 |
Why?
|
| Monocytes | 2 | 2005 | 118 | 0.060 |
Why?
|
| Luteinizing Hormone | 1 | 2005 | 16 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2005 | 46 | 0.060 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2005 | 1 | 0.060 |
Why?
|
| Testosterone | 1 | 2005 | 48 | 0.060 |
Why?
|
| Canarypox virus | 1 | 2005 | 1 | 0.060 |
Why?
|
| Species Specificity | 1 | 2005 | 98 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 65 | 0.060 |
Why?
|
| Lectins, C-Type | 1 | 2005 | 14 | 0.060 |
Why?
|
| Mice, Inbred CBA | 1 | 2005 | 7 | 0.060 |
Why?
|
| Asbestos | 1 | 2005 | 2 | 0.060 |
Why?
|
| Antibodies | 1 | 2005 | 55 | 0.060 |
Why?
|
| Birds | 1 | 2005 | 3 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 2 | 2019 | 62 | 0.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2005 | 11 | 0.050 |
Why?
|
| Fever | 1 | 2005 | 60 | 0.050 |
Why?
|
| Carcinogens | 1 | 2005 | 36 | 0.050 |
Why?
|
| Fatigue | 1 | 2005 | 80 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 458 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 78 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2004 | 26 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 77 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 129 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2004 | 65 | 0.050 |
Why?
|
| Muscles | 1 | 2004 | 69 | 0.050 |
Why?
|
| Baculoviridae | 1 | 2004 | 6 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2004 | 23 | 0.050 |
Why?
|
| Lipid A | 1 | 2004 | 4 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2003 | 22 | 0.050 |
Why?
|
| Disulfides | 1 | 2003 | 43 | 0.050 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2003 | 6 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2003 | 7 | 0.050 |
Why?
|
| Cell Line | 4 | 2005 | 443 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2003 | 52 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2003 | 93 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2003 | 167 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2005 | 1840 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 422 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2019 | 36 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 305 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 97 | 0.040 |
Why?
|
| Lanthanoid Series Elements | 1 | 2019 | 2 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2019 | 114 | 0.040 |
Why?
|
| Alpha Particles | 1 | 2019 | 7 | 0.040 |
Why?
|
| Chelating Agents | 1 | 2019 | 16 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2019 | 73 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2020 | 3612 | 0.040 |
Why?
|
| Radiometry | 1 | 2019 | 52 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 287 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2013 | 478 | 0.030 |
Why?
|
| Time Factors | 2 | 2013 | 2196 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 896 | 0.030 |
Why?
|
| Psychology | 1 | 2016 | 25 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 83 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2015 | 43 | 0.030 |
Why?
|
| Cell Division | 2 | 2006 | 91 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 394 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 5 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2014 | 12 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2014 | 15 | 0.030 |
Why?
|
| Rats | 1 | 2019 | 1892 | 0.030 |
Why?
|
| Gastrointestinal Hormones | 1 | 2014 | 1 | 0.030 |
Why?
|
| Immunization | 2 | 2005 | 41 | 0.030 |
Why?
|
| Neuropeptides | 1 | 2014 | 23 | 0.030 |
Why?
|
| Cell Separation | 1 | 2014 | 86 | 0.030 |
Why?
|
| Gene Transfer Techniques | 2 | 2003 | 58 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2014 | 178 | 0.020 |
Why?
|
| DNA Probes | 1 | 2012 | 18 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 276 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 52 | 0.020 |
Why?
|
| Vinblastine | 1 | 2011 | 4 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2011 | 9 | 0.020 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2011 | 12 | 0.020 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2011 | 12 | 0.020 |
Why?
|
| Cisplatin | 1 | 2011 | 77 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2011 | 9 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2011 | 31 | 0.020 |
Why?
|
| Cytotoxins | 1 | 2011 | 13 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 172 | 0.020 |
Why?
|
| Sarcoma | 1 | 2011 | 82 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 22 | 0.020 |
Why?
|
| DNA Damage | 1 | 2011 | 90 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 189 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 971 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 286 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 101 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2009 | 62 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 34 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2008 | 85 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 544 | 0.020 |
Why?
|
| Etidronic Acid | 1 | 2006 | 3 | 0.020 |
Why?
|
| Imidazoles | 1 | 2006 | 97 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2006 | 248 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 767 | 0.010 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2005 | 10 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 19 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 33 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 3938 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2004 | 1 | 0.010 |
Why?
|
| Emulsions | 1 | 2004 | 8 | 0.010 |
Why?
|
| Mineral Oil | 1 | 2004 | 4 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2004 | 13 | 0.010 |
Why?
|
| Skin Tests | 1 | 2004 | 13 | 0.010 |
Why?
|
| Immunoglobulin Fragments | 1 | 2003 | 1 | 0.010 |
Why?
|
| Staphylococcal Protein A | 1 | 2003 | 3 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2004 | 58 | 0.010 |
Why?
|
| Bacteriophage T4 | 1 | 2003 | 1 | 0.010 |
Why?
|
| Capsid | 1 | 2003 | 8 | 0.010 |
Why?
|
| Liposomes | 1 | 2004 | 35 | 0.010 |
Why?
|
| Adenoviridae Infections | 1 | 2003 | 15 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 90 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2003 | 30 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2004 | 112 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2004 | 103 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 1073 | 0.010 |
Why?
|